<http://webisa.webdatacommons.org/prov/344056679>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/151180130> .
<http://webisa.webdatacommons.org/151180130>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/151180130>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<researchgate.net> .
<http://webisa.webdatacommons.org/151180130>	<http://www.w3.org/ns/prov#value>	"Due to its known safety and efficacy, IT-S will be particularly suitable for patients with SSNHL who have chronic diseases such as diabetes mellitus, hypertension, or chronic renal failure." .
<http://webisa.webdatacommons.org/prov/110028512>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/151180130> .